This year the Group expects a higher volume of diagnostic services, exceeding 385,000 procedures compared to 373,000 provided at Voxel, RP, Scanix last year (2x2H22).
More efficient usage of active labs and faster processing of scans should support the profitability. The Group carries out investments in 2 new MRI laboratories Będzin and Sędziszów and replaces a CT scanner in Bydgoszcz. A launch of a new CT laboratory is planned in Kraków, MRI and CT scanners will be replaced in Warsaw (MRI, CT) and Bytom (CT).
Besides, the Group looks at takeover targets and considers options to lower losses generated by the hospital business or soften the impact it exerts on the Group’s financials. According to our estimates, the hospital business may burden the Company’s consolidated EBIT by c. PLN 6 million.
The current restructuring includes (i) reducing the number of hospital beds in the internal diseases ward with their increase elsewhere, (ii) a hospital stay optimization with more efficient use of hospitals beds, (iii) providing services within the framework of the colorectal cancer screening program (from December 1, 2022), (iv) increasing the medical staff in endoscopic units, (v) salary costs restructuring, and (vi) starting the cooperation in the clinical tests area.
